References

A tale of coronary artery disease and myocardial infarction

10.1056/nejmra1112570 · 2012 · External reference

Global Burden of Cardiovascular Diseases Risks 2023 Collaborators. Global, regional, and national burden of cardiovascular diseases and risk factors in 204 countries and territories, 1990-2023

2025 · External reference

Obesity in adults

10.1016/s0140-6736(24)01210-8 · 2024 · External reference

Effect of weight loss on blood pressure changes in overweight patients: a systematic review and meta-analysis

10.1111/jch.14661 · 2023 · External reference

Metabolic mediators of the effects of body-mass index, overweight, and obesity on coronary heart disease and stroke: a pooled analysis of 97 prospective cohorts with 1.8 million participants

10.1016/s0140-6736(13)61836-x · 2014 · External reference

Cardiovascular-liver-metabolic health: Recommendations in screening, diagnosis, and management of metabolic dysfunction-associated steatotic liver disease in cardiovascular disease via modified Delphi approach

10.1161/circulationaha.124.070535 · 2025 · External reference

Association of initial and longitudinal changes in C-reactive protein with the risk of cardiovascular disease, cancer, and mortality

10.1016/j.mayocp.2022.10.013 · 2023 · External reference

Inflammation and Cardiovascular Disease: 2025 ACC Scientific Statement: A Report of the American College of Cardiology

2025 · External reference

Nutrient-Stimulating Hormone-Based Therapies for Obesity

10.1016/j.ecl.2024.10.006 · 2025 · External reference

A structural basis for amylin receptor phenotype

10.1126/science.abm9609 · 2022 · External reference

Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial

10.1016/s0140-6736(21)01751-7 · 2021 · External reference

Amylin - Its role in the homeostatic and hedonic control of eating and recent developments of amylin analogs to treat obesity

10.1016/j.molmet.2017.11.009 · 2018 · External reference

Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2.4 mg for weight management: a randomised, controlled, phase 1b trial

10.1016/s0140-6736(21)00845-x · 2021 · External reference

Effects of semaglutide on beta cell function and glycaemic control in participants with type 2 diabetes: a randomised, double-blind, placebo-controlled trial

10.1007/s00125-017-4289-0 · 2017 · External reference

Semaglutide and cardiovascular outcomes in patients with type 2 diabetes

10.1056/nejmoa1607141 · 2016 · External reference

Oral semaglutide and cardiovascular outcomes in high-risk type 2 diabetes

10.1056/nejmoa2501006 · 2025 · External reference

Cardiovascular and kidney outcomes and mortality with long-acting injectable and oral glucagon-like peptide 1 receptor agonists in individuals with type 2 diabetes: a systematic review and meta-analysis of randomized trials

2025 · External reference

Semaglutide and cardiovascular outcomes in obesity without diabetes

10.1056/nejmoa2307563 · 2023 · External reference

Semaglutide and walking capacity in people with symptomatic peripheral artery disease and type 2 diabetes (STRIDE): a phase 3b, double-blind, randomised, placebo-controlled trial

10.1016/s0140-6736(25)00509-4 · 2025 · External reference

Efficacy and safety of co-administered once-weekly cagrilintide 2.4 mg with once-weekly semaglutide 2.4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial

10.1016/s0140-6736(23)01163-7 · 2023 · External reference

Coadministered cagrilintide and semaglutide in adults with overweight or obesity

10.1056/nejmoa2502081 · 2025 · External reference

Cagrilintide-semaglutide in adults with overweight or obesity and type 2 diabetes

10.1056/nejmoa2502082 · 2025 · External reference

CagriSema reduces blood pressure in adults with overweight or obesity: REDEFINE 1

10.1161/hypertensionaha.125.26055 · 2026 · External reference

Cagrilintide-semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2): a double-blind, randomised, controlled, phase 3 study

10.1016/s2213-8587(26)00125-7 · 2026 · External reference

Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients

10.1056/nejmoa2215024 · 2023 · External reference

Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease

10.1056/nejmoa1615664 · 2017 · External reference

Tirzepatide for reduction of morbidity and mortality in adults with obesity: rationale and design of the SURMOUNT-MMO trial

10.1002/oby.24332 · 2025 · External reference

Evolocumab in Patients without a Previous Myocardial Infarction or Stroke

10.1056/nejmoa2514428 · 2026 · External reference

2017 cardiovascular and stroke endpoint definitions for clinical trials

10.1161/circulationaha.117.033502 · 2018 · External reference

Unresolved reference

External reference

Unresolved reference

External reference

Graphical approaches for multiple comparison procedures using weighted Bonferroni, Simes, or parametric tests

10.1002/bimj.201000239 · 2011 · External reference

Lipid-lowering treatment patterns and risk of subsequent cardiovascular outcomes in patients with recent coronary revascularization

2026 · External reference

Oral semaglutide and heart failure outcomes in persons with type 2 diabetes: a secondary analysis of the SOUL randomized clinical trial

10.1001/jamainternmed.2025.7774 · 2026 · External reference

Effect of GLP-1 receptor agonists and co-agonists on atrial fibrillation risk in overweight or obesity: systematic review and meta-analysis of randomized controlled trials

10.1016/j.metabol.2025.156463 · 2026 · External reference

Once-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis

10.1056/nejmoa2403664 · 2024 · External reference

Body Composition Changes After Bariatric Surgery or Treatment With GLP-1 Receptor Agonists

10.1001/jamanetworkopen.2025.53323 · 2026 · External reference

Exploratory mediation analysis of the effect of semaglutide on cardiovascular outcomes in people with overweight or obesity in the SELECT randomised trial

2024 · External reference

Semaglutide and cardiovascular outcomes by baseline and changes in adiposity measurements: a prespecified analysis of the SELECT trial

10.1016/s0140-6736(25)01375-3 · 2025 · External reference

Semaglutide and cardiovascular outcomes by baseline HbA1c and change in HbA1c in people with overweight or obesity but without diabetes in SELECT

10.2337/dc24-0764 · 2024 · External reference

Cardiovascular actions and clinical outcomes with glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors

10.1161/circulationaha.117.028136 · 2017 · External reference

Semaglutide in patients with obesity-related heart failure and type 2 diabetes

10.1056/nejmoa2313917 · 2024 · External reference

Effect of Semaglutide on Atrial Arrhythmias Recurrence Following Ablation for Atrial Fibrillation: A Prospective Study

10.1161/circep.125.014069 · 2025 · External reference

Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis

10.1056/nejmoa2413258 · 2025 · External reference

Impact of semaglutide on high-sensitivity C-reactive protein: exploratory patient-level analyses of SUSTAIN and PIONEER randomized clinical trials

10.1186/s12933-022-01585-7 · 2022 · External reference

Impact of oral semaglutide on cardiovascular risk factors in patients with type 2 diabetes and atherosclerotic cardiovascular disease and/or chronic kidney disease: a SOUL post hoc analysis

2025 · External reference

Semaglutide, inflammatory markers and cardiovascular outcomes in patients with overweight or obesity in the select trial

2024 · External reference

Inflammation and cardiovascular disease: 2025 ACC scientific statement: a report of the American College of Cardiology

2025 · External reference

Transitioning to active-controlled trials to evaluate cardiovascular safety and efficacy of medications for type 2 diabetes

10.1186/s12933-022-01601-w · 2022 · External reference

Cardiovascular outcomes with tirzepatide versus dulaglutide in type 2 diabetes

10.1056/nejmoa2505928 · 2025 · External reference

Amylin and the renin-angiotensin system: risk or opportunity in amylin-based therapy?

10.1016/s0140-6736(25)01776-3 · 2026 · External reference

Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes

10.1056/nejmoa1901118 · 2019 · External reference